SELECTA BIOSCIENCES, INC.
Biotech · Acquired
Biodegradable nanoparticles (PLGA-based) delivering antigens and immunosuppressive drugs to induce antigen-specific immune tolerance
- Grants
- $225K
- 1 award
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 24
- 0 granted · 24 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152016
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Nanoparticles for Immune Tolerance to FVIII | $225,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2931 | Annias Immunotherapeutics, Inc. | — | — |
| 2932 | INDUSTRIAL SONOMECHANICS, LLC | — | — |
| 2933 | ADEPTHERA, LLC | — | — |
| 2934 | SELECTA BIOSCIENCES, INC. | — | — |
| 2935 | QUANTUMBIO INC | — | — |
| 2936 | CBS THERAPEUTICS, INC. | — | — |
| 2937 | Dayra Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods Of Administering Immunosuppressants Having A Specified Pharmacodynamic Effective Life And Therapeutic Macromolecules For The Induction Of Immune Toleranceapplication
- Tolerogenic Synthetic Nanocarriers For Allergy Therapyapplication
- Tolerogenic Synthetic Nanocarriersapplication
- Viral Vector Dosing Protocolsapplication
- High Affinity IL-2 Receptor Agonists And Immunosuppressants To Enhance Immune Toleranceapplication
- Synthetic Nanocarriers Comprising An Immunosuppressant In Combination With High Affinity IL-2 Receptor Agonists And Anti-igm Agentsapplication
- Methods And Compositions For Attenuating Anti-viral Transfer Vector Immune Responsesapplication
- Immunosuppressants In Combination With Anti-igm Agents And Related Dosingapplication
- Immunosuppressant In Combination With High Affinity IL-2 Receptor Agonists And Related Dosingapplication
- Tolerogenic Synthetic Nanocarriers To Reduce Immune Responses To Therapeutic Proteinsapplication
- Immunosuppressant In Combination With High Affinity IL-2 Receptor Agonists For Diabetesapplication
- Modulation Of High Affinity IL-2 Receptor Agonist Effects With Immunosuppressantapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.